Seratrials: Biological Samples Collection About the study? PROSPECTIVE COLLECTION OF CEREBRAL SPINAL FLUID (CSF), WHOLE BLOOD, NASAL SWABS, URINE AND SALIVA SAMPLES FROM SUBJECTS DIAGNOSED WITH OR SUSPECTED TO HAVE NEUROLOGICAL DISORDERS, COGNITIVE IMPAIRMENT, OR INFECTIONS OF CSF AND NORMAL CONTROLS FOR RESEARCH Purpose of the study? SeraTrials is a biotechnology company that partners with […]
Biohaven BHV7000 Rise Focal Epilepsy Study About the study? Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems. Purpose of the study? The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main question it aims to
RxFunction Balance4Mobility: Walkasin’s Device Read More »
BMS TARGET-TAU This study is being done to learn more about the safety and efficacy of an investigational medication called BMS-986446 in adults aged 50-80 years with mild cognitive impairment due to Alzheimer’s disease, or mild Alzheimer’s dementia. Inclusion Criteria: Are 50-80 years old Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease,
Sanofi Freviva The purpose of this study is to determine the efficacy of frexalimab in delaying the disability progression and the safety in participants with non-relapsing secondary progressive multiple sclerosis. Inclusion Criteria: 18-60 years of age, a diagnosis of non-relapsing secondary progressive multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years, without clinical
PIPELINE/CONTINEUM VISTA This is a randomized, double-blind study of PIPE-307 or placebo to see if it can help patients with relapsing-remitting multiple sclerosis. Inclusion Criteria: 18-50 years of age, a diagnosis of relapsing-remitting multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years Without clinical MS relapse or treatment with corticosteroids within last 6
PIPELINE/CONTINEUM VISTA Read More »
BIOGEN CELIA In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on
Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study: 25 Years to 50 Years (Adult) Sexes Eligible for Study: All Generation HD-2 Link
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
